Search

Displaying results 1111 - 1120 of 1279 in total
  1. Drug

    Denosumab

    go.drugbank.com/drugs/DB06643
    ApprovedInvestigational

    Two denosumab biosimilars—Wyost® (denosumab-bbdz) [L53063] and Jubbonti® (denosumab-bbdz)[L53058]—were approved by the FDA in March 2024 for all indications of the reference products Xgeva® and Prolia®

  2. Drug

    Estradiol dienanthate

    go.drugbank.com/drugs/DB13955
    ApprovedVet approvedWithdrawn

    Estradiol is the most potent form of all mammalian estrogenic steroids and acts as the major female sex hormone.

  3. Drug

    Dostarlimab

    go.drugbank.com/drugs/DB15627
    ApprovedInvestigational

    A prospective phase II study in patients with mismatch repair-deficient locally advanced rectal cancer resulted in all twelve patients exhibiting a complete clinical response.[A248905]

  4. Drug

    Bamlanivimab

    go.drugbank.com/drugs/DB15718
    ApprovedInvestigational

    with [etesevimab] to treat mild to moderate COVID-19 in adults and pediatric patients who are at high risk for progressing to severe COVID-19:[L40179] this EUA later expanded in December 2021 to include all

  5. Drug

    Gallium Ga-68 gozetotide

    go.drugbank.com/drugs/DB16019
    ApprovedInvestigational

    [A225396] In nearly all prostate cancers, malignant cells express a transmembrane protein called prostate-specific membrane antigen (PSMA).

  6. Drug

    AT1391

    go.drugbank.com/drugs/DB05120
    Experimental

    AT1391 is a daily insulin skin patch designed to provide continuous basal levels of insulin for patients with diabetes.

  7. Drug

    99mTc-14 F7 Mab

    go.drugbank.com/drugs/DB05867
    Experimental

    99mTc 14F7 Mab has strong anti tumor activity against myeloma cells in vivo. Growth inhibition and prolonged survival of the myeloma tumor were obtained as evidences of anti tumor effect after treatment with 99mTc 14F7 Mab.

  8. Drug

    IGN311

    go.drugbank.com/drugs/DB04988
    Experimental

    IGN311 is a humanized monoclonal antibody (mab) against the Lewis Y carbohydrate antigen, a blood-group-related oligosaccharide.

  9. Drug

    SF1126

    go.drugbank.com/drugs/DB05210
    Investigational

    SF1126 is an integrin-targeted PI3 kinase inhibitor.

  10. Drug

    Lactulose

    go.drugbank.com/drugs/DB00581
    ApprovedInvestigational

    Lactulose is a synthetic disaccharide derivative of lactose that is most commonly used as a laxative agent despite also being formally indicated to serve as an adjunct therapy in treating portal-systemic encephalopathy (PSE).[FDA Label,L...